Loading
A phase 3 trial testing QL1706 in non-small-cell lung cancer, active and no longer recruiting.
A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer is a phase 3 interventional study registered as NCT05690945, led by Qilu Pharmaceutical, and active but no longer recruiting on the registry. Official title: A Randomised, Double-blind, Multicenter Phase 3 Clinical Study to Evaluate the Efficacy and Safety of QL1706 in Combination With Chemotherapy in First-line PD-L1 Negative, Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients. Planned enrolment is 606 participants (actual). The study started in 2023-02-15 and primary completion is expected in 2029-06. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares QL1706, Qilu Pharmaceutical, Non-small-cell lung cancer.
Shares QL1706, Qilu Pharmaceutical.
Shares QL1706, Qilu Pharmaceutical.
Shares QL1706, Qilu Pharmaceutical.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/